Immune activation and antibody responses in non-progressing elite controller individuals infected with HIV-1

Journal of Medical Virology

Volumn 81, Issue 10, 2009, Pages 1681-1690

  Bello, Gonzalo ^a   Velasco de Castro, Carlos A ^a   Bongertz, Vera ^a   Santos Rodrigues, Caio A ^a   Giacoia Gripp, Carmem B W ^a   Pilotto, Jose H ^b   Grinsztejn, Beatriz ^b   Veloso, Valdilea G ^b   Morgado, Mariza G ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Funda??o Oswaldo Cruz   (Brazil)

Author keywords

Antibody avidity; Binding antibodies; Chronic activation; HIV controllers; Long term non progressors

Indexed keywords

BETA 2 MICROGLOBULIN; CD38 ANTIGEN; HLA DR ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; LYMPHOCYTE SUBPOPULATION; MALE; T LYMPHOCYTE ACTIVATION; VIREMIA;

ADULT; ANTIBODY AFFINITY; ANTIBODY FORMATION; BETA 2-MICROGLOBULIN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 69949153012     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21565     Document Type: Article

References (51)

1. Altfeld M, Addo MM, Rosenberg ES, Hecht FM, Lee PK, Vogel M, Yu XG, Draenert R, Johnston MN, Strick D, Allen TM, Feeney ME, Kahn JO, Sekaly RP, Levy JA, Rockstroh JK, Goulder PJ, Walker BD. 2003. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS 17:2581-2591. (Pubitemid 38402336)
2. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debre P, Leibowitch J. 1997. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277:112-116. (Pubitemid 27450659)
3. Bailey JR, Lassen KG, Yang HC, Quinn TC, Ray SC, Blankson JN, Siliciano RF. 2006. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol 80:4758-4770.
4. Barker E, Mackewicz CE, Reyes-Teran G, Sato A, Stranford SA, Fujimura SH, Christopherson C, Chang SY, Levy JA. 1998. Virological and immunological features of long-term human immunodeficiency virus-infected individuals who have remained asymptomatic compared with those who have progressed to acquired immunodeficiency syndrome. Blood 92:3105-3114. (Pubitemid 28492316)
5. Bello G, Casado C, Sandonis V, Alonso-Nieto M, Vicario JL, Garcia S, Hernando V, Rodriguez C, del Romero J, Lopez-Galindez C. 2005. A subset of human immunodeficiency virus type 1 long-term nonprogressors is characterized by the unique presence of ancestral sequences in the viral population. J Gen Virol 86:355-364. (Pubitemid 40227947)
6. Bello G, Casado C, Sandonis V, Alvaro-Cifuentes T, Dos Santos CA, Garcia S, Rodriguez C, Del Romero J, Pilotto JH, Grinsztejn B, Veloso VG, Morgado MG, Lopez-Galindez C. 2007. Plasma viral load threshold for sustaining intrahost HIV type 1 evolution. AIDS Res Hum Retroviruses 23:1242-1250. (Pubitemid 350017603)
7. Binley JM, Trkola A, Ketas T, Schiller D, Clas B, Little S, Richman D, Hurley A, Markowitz M, Moore JP. 2000. The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection. J Infect Dis 182:945-949. (Pubitemid 30695396)
8. Bisset LR, Cone RW, Huber W, Battegay M, Vernazza PL, Weber R, Grob PJ, Opravil M. 1998. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study. AIDS 12:2115-2123. (Pubitemid 28495265)
9. Bongertz V, Ouverney EP, Fernandez SC, Grinsztejn B, Veloso V, Couto-Fernandez JC, Pilotto JH, Morgado MG. 2007. Anti-human immunodeficiency virus type 1 humoral immune response and highly active antiretroviral treatment. Mem Inst Oswaldo Cruz 102:817-825. (Pubitemid 350248738)
10. Bouscarat F, Levacher M, Landman R, Muffat-Joly M, Girard PM, Saimot AG, Brun-Vezinet F, Sinet M. 1998. Changes in blood CD8+ lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy. AIDS 12:1267-1273. (Pubitemid 28330718)
11. Buchbinder S, Vittinghoff E. 1999. HIV-infected long-term nonprogressors: Epidemiology, mechanisms of delayed progression, and clinical and research implications. Microbes Infect 1:1113-1120. (Pubitemid 29496094)
12. Collaborative Group on AIDS Incubation and HIV Survival and Including the CASCADE (Concerted Action on SeroConversion to AIDS and Death in Europe) Collaboration. 2000. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: A collaborative re-analysis. Lancet 355:1131-1137.
13. Deeks SG, Walker BD. 2007. Human immunodeficiency virus controllers: Mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27:406-416.
14. Delwart EL, Pan H, Sheppard HW, Wolpert D, Neumann AU, Korber B, Mullins JI. 1997. Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS. J Virol 71:7498-7508. (Pubitemid 27391690)
15. Ferbas J, Kaplan AH, Hausner MA, Hultin LE, Matud JL, Liu Z, Panicali DL, Nerng-Ho H, Detels R, Giorgi JV. 1995. Virus burden in long-term survivors of human immunodeficiency virus (HIV) infection is a determinant of anti-HIV CD8+ lymphocyte activity. J Infect Dis 172:329-339.
16. Giorgi JV, Majchrowicz MA, Johnson TD, Hultin P, Matud J, Detels R. 1998. Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection. AIDS 12:1833-1844. (Pubitemid 28454449)
17. Greenough TC, Sullivan JL, Desrosiers RC. 1999. Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1. N Engl J Med 340:236-237.
18. Hare CB, Pappalardo BL, Busch MP, Karlsson AC, Phelps BH, Alexander SS, Bentsen C, Ramstead CA, Nixon DF, Levy JA, Hecht FM. 2006. Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection. Clin Infect Dis 42:700-708. (Pubitemid 43271387)
19. Hatano H, Delwart EL, Norris PJ, Lee TH, Dunn-Williams J, Hunt PW, Hoh R, Stramer SL, Linnen JM, McCune JM, Martin JN, Busch MP, Deeks SG. 2009. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol 83:329-335.
20. Hayashida T, Gatanaga H, Tanuma J, Oka S. 2008. Effects of low HIV type 1 load and antiretroviral treatment on IgG-capture BED-enzyme immunoassay. AIDS Res Hum Retroviruses 24:495-498.
21. Hagervorst E, Jurriaans S, de Wolf F, van Wijk A, Wiersma A, Valk M, Roos M, Van Gemen B, Coutinho R, Miedena F, Goudsmit J. 1995. Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: Low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J Infect Dis 171:811-821.
22. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K, Hsue P, Emu B, Krone M, Lampiris H, Douek D, Martin JN, Deeks SG. 2008. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 197:126-133. (Pubitemid 351263476)
23. Jin X, Ogg G, Bonhoeffer S, Safrit J, Vesanen M, Bauer D, Chen D, Cao Y, Demoitie MA, Zhang L, Markowitz M, Nixon D, McMichael A, Ho DD. 2000. An antigenic threshold for maintaining human immunodeficiency virus type 1-specific cytotoxic T lymphocytes. Mol Med 6:803-809.
24. Kassutto S, Johnston MN, Rosenberg ES. 2005. Incomplete HIV type 1 antibody evolution and seroreversion in acutely infected individuals treated with early antiretroviral therapy. Clin Infect Dis 40:868-873. (Pubitemid 40365508)
25. Killian MS, Norris PJ, Rawal BD, Lebedeva M, Hecht FM, Levy JA, Busch MP. 2006. The effects of early antiretroviral therapy and its discontinuation on the HIV-specific antibody response. AIDS Res Hum Retroviruses 22:640-647. (Pubitemid 44061400)
26. Kloosterboer N, Groeneveld PH, Jansen CA, van der Vorst TJ, Koning F, Winkel CN, Duits AJ, Miedema F, van Baarle D, van Rij RP, Brinkman K, Schuitemaker H. 2005. Natural controlled HIV infection: Preserved HIV-specific immunity despite undetectable replication competent virus. Virology 339:70-80. (Pubitemid 41102170)
27. Laeyendecker O, Rothman RE, Henson C, Horne BJ, Ketlogetswe KS, Kraus CK, Shahan J, Kelen GD, Quinn TC. 2008. The effect of viral suppression on cross-sectional incidence testing in the Johns Hopkins Hospital Emergency Department. J Acquir Immune Defic Syndr 48:211-215.
28. Lambotte O, Boufassa F, Madec Y, Nguyen A, Goujard C, Meyer L, Rouzioux C, Venet A, Delfraissy JF. 2005. HIV controllers: A homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 41:1053-1056. (Pubitemid 41368233)
29. Learmont JC, Geczy AF, Mills J, Ashton LJ, Raynes-Greenow CH, Garsia RJ, Dyer WB, McIntyre L, Oelrichs RB, Rhodes DI, Deacon NJ, Sullivan JS. 1999. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N Engl J Med 340:1715-1722. (Pubitemid 29252599)
30. Lefrere JJ, Morand-Joubert L, Mariotti M, Bludau H, Burghoffer B, Petit JC, Roudot-Thoraval F. 1997. Even individuals considered as long-term nonprogressors show biological signs of progression after 10 years of human immunodeficiency virus infection. Blood 90:1133-1140. (Pubitemid 27314149)
31. Lefrere JJ, Mariotti M, Morand-Joubert L, Thauvin M, Roudot-Thoraval F. 1999. Plasma human immunodeficiency virus RNA below 40 copies/mL is rare in untreated persons even in the first years of infection. J Infect Dis 180:526-529. (Pubitemid 30256341)
32. Lifson AR, Buchbinder SP, Sheppard HW, Mawle AC, Wilber JC, Stanley M, Hart CE, Hessol NA, Holmberg SD. 1991. Long-term human immunodeficiency virus infection in asymptomatic homosexual and bisexual men with normal CD4+ lymphocyte counts: Immunologic and virologic characteristics. J Infect Dis 163:959-965.
33. Loffredo JT, Maxwell J, Qi Y, Glidden CE, Borchardt GJ, Soma T, Bean AT, Beal DR, Wilson NA, Rehrauer WM, Lifson JD, Carrington M, Watkins DI. 2007. Mamu-B*08-positive macaques control Simian immunodeficiency virus replication. J Virol 81:8827-8832. (Pubitemid 47242856)
34. Madec Y, Boufassa F, Porter K, Meyer L. 2005a. Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters. AIDS 19:2001-2007. (Pubitemid 41669025)
35. Madec Y, Boufassa F, Rouzioux C, Delfraissy JF, Meyer L. 2005b. Undetectable viremia without antiretroviral therapy in patients with HIV seroconversion: An uncommon phenomenon? Clin Infect Dis 40:1350-1354.
36. Markowitz M, Vesanen M, Tenner-Racz K, Cao Y, Binley JM, Talal A, Hurley A, Jin X, Chaudhry MR, Yaman M, Frankel S, Heath-Chiozzi M, Leonard JM, Moore JP, Racz P, Nixon DF, Ho DD. 1999. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis 179:527-537. (Pubitemid 30016135)
37. Morris L, Binley JM, Clas BA, Bonhoeffer S, Astill TP, Kost R, Hurley A, Cao Y, Markowitz M, Ho DD, Moore JP. 1998. HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J Exp Med 188:233-245. (Pubitemid 28357752)
38. Parekh BS, McDougal JS. 2005. Application of laboratory methods for estimation of HIV-1 incidence. Indian J Med Res 121:510-518. (Pubitemid 40691380)
39. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, Baker B, Trocha A, Rosenberg R, Mackey E, Ueda P, Lu Z, Cohen D, Wrin T, Petropoulos CJ, Rosenberg ES, Walker BD. 2008. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 197:563-571. (Pubitemid 351321534)
40. Rodes B, Toro C, Paxinos E, Poveda E, Martinez-Padial M, Benito JM, Jimenez V, Wrin T, Bassani S, Soriano V. 2004. Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection. AIDS 18:1109-1116. (Pubitemid 38738510)
41. Sajadi MM, Heredia A, Le N, Constantine NT, Redfield RR. 2007. HIV-1 natural viral suppressors: Control of viral replication in the absence of therapy. AIDS 21:517-519. (Pubitemid 46263263)
42. Selleri M, Orchi N, Zaniratti MS, Bellagamba R, Corpolongo A, Angeletti C, Ippolito G, Capobianchi MR, Girardi E. 2007. Effective highly active antiretroviral therapy in patients with primary HIV-1 infection prevents the evolution of the avidity of HIV-1-specific antibodies. J Acquir Immune Defic Syndr 46:145-150. (Pubitemid 47482609)
43. Sheppard HW, Lang W, Ascher MS, Vittinghoff E, Winkelstein W. 1993. The characterization of non-progressors: Long-term HIV-1 infection with stable CD4+ T-cell levels. AIDS 7:1159-1166. (Pubitemid 23270961)
44. Shioda T, Oka S, Xin X, Liu H, Harukuni R, Kurotani A, Fukushima M, Hasan MK, Shiino T, Takebe Y, Iwamoto A, Nagai Y. 1997. In vivo sequence variability of human immunodeficiency virus type 1 envelope gp120: Association of V2 extension with slow disease progression. J Virol 71:4871-4881.
45. Suligoi B, Galli C, Massi M, Di Sora F, Sciandra M, Pezzotti P, Recchia O, Montella F, Sinicco A, Rezza G. 2002. Precision and accuracy of a procedure for detecting recent human immunodeficiency virus infections by calculating the antibody avidity index by an automated immunoassay-based method. J Clin Microbiol 40:4015-4020. (Pubitemid 35285783)
46. Suligoi B, Massi M, Galli C, Sciandra M, Di Sora F, Pezzotti P, Recchia O, Montella F, Sinicco A, Rezza G. 2003. Identifying recent HIV infections using the avidity index and an automated enzyme immunoassay. J Acquir Immune Defic Syndr 32:424-428. (Pubitemid 36363157)
47. Verity EE, Zotos D, Wilson K, Chatfield C, Lawson VA, Dwyer DE, Cunningham A, Learmont J, Dyer W, Sullivan J, Churchill M, Wesselingh SL, Gabuzda D, Gorry PR, McPhee DA. 2007. Viral phenotypes and antibody responses in long-term survivors infected with attenuated human immunodeficiency virus type 1 containing deletions in the nef and long terminal repeat regions. J Virol 81:9268-9278. (Pubitemid 47311469)
48. Wang B, Dyer WB, Zaunders JJ, Mikhail M, Sullivan JS, Williams L, Haddad DN, Harris G, Holt JA, Cooper DA, Miranda-Saksena M, Boadle R, Kelleher AD, Saksena NK. 2002. Comprehensive analyses of a unique HIV-1-infected nonprogressor reveal a complex association of immunobiological mechanisms in the context of replication-incompetent infection. Virology 304:246-264. (Pubitemid 36069167)
49. Wang B, Mikhail M, Dyer WB, Zaunders JJ, Kelleher AD, Saksena NK. 2003. First demonstration of a lack of viral sequence evolution in a nonprogressor, defining replication-incompetent HIV-1 infection. Virology 312:135-150. (Pubitemid 36918466)
50. Wolinsky SM, Korber BT, Neumann AU, Daniels M, Kunstman KJ, Whetsell AJ, Furtado MR, Cao Y, Ho DD, Safrit JT. 1996. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 272:537-542. (Pubitemid 26138195)
51. Zaunders JJ, Geczy AF, Dyer WB, McIntyre LB, Cooley MA, Ashton LJ, Raynes-Greenow CH, Learmont J, Cooper DA, Sullivan JS. 1999. Effect of long-term infection with nef-defective attenuated HIV type 1 on CD4+ and CD8+ T lymphocytes: Increased CD45RO+CD4+ T lymphocytes and limited activation of CD8+ T lymphocytes. AIDS Res Hum Retroviruses 15:1519-1527.